Journal ArticleDOI
Monoclonal antibody successes in the clinic
TLDR
Most monoclonal antibodies in clinical trials are owned by small biotech companies, but with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.Abstract:
Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.read more
Citations
More filters
Journal ArticleDOI
Potent antibody therapeutics by design
TL;DR: The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential.
Journal ArticleDOI
Therapeutic antibodies: successes, limitations and hopes for the future.
TL;DR: An overview of the current state of the art of monoclonal antibodies is given and the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents are described.
Journal ArticleDOI
Development trends for human monoclonal antibody therapeutics
TL;DR: Data is analysed on 147 human mAbs that have entered clinical study to highlight trends in their development and approval, which may help inform future studies of this class of therapeutic agents.
Journal ArticleDOI
The safety and side effects of monoclonal antibodies
TL;DR: Some of the adverse effects encountered with mAb therapies are reviewed, and advances in preclinical testing and antibody technology aimed at minimizing the risk of these events are discussed.
Journal ArticleDOI
Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules
Makoto Mitsunaga,Mikako Ogawa,Nobuyuki Kosaka,Lauren T Rosenblum,Peter L. Choyke,Hisataka Kobayashi +5 more
TL;DR: A new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors is developed.
References
More filters
Journal ArticleDOI
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more
TL;DR: The derivation of a number of tissue culture cell lines which secrete anti-sheep red blood cell (SRBC) antibodies is described here, made by fusion of a mouse myeloma and mouse spleen cells from an immunised donor.
Journal ArticleDOI
Can the pharmaceutical industry reduce attrition rates
Ismail Kola,John Landis +1 more
TL;DR: The pharmaceutical industry faces considerable challenges, both politically and fiscally, and the fiscal pressures that face the industry from the perspective of R&D are dealt with.
Journal ArticleDOI
Replacing the complementarity-determining regions in a human antibody with those from a mouse
TL;DR: This work substituted the CDRs from the heavy-chain variable region of mouse antibody B1–8, which binds the hapten NP-cap, for the corresponding CDRs of a human myeloma protein, to determine whether the antigen-binding site could be transplanted from one framework to another by grafting theCDRs.
Journal ArticleDOI
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains
TL;DR: Chimeric genes were constructed that utilized the rearranged and expressed antigen-binding variable region exons from the myeloma cell line S107, which produces an IgA (kappa) anti-phosphocholine antibody as discussed by the authors.
Journal ArticleDOI
Production of functional chimaeric mouse/human antibody
Gabrielle L. Boulianne,Gabrielle L. Boulianne,Gabrielle L. Boulianne,Nobumichi Hozumi,Nobumichi Hozumi,Marc J. Shulman,Marc J. Shulman +6 more
TL;DR: In this article, the authors constructed immunoglobulin genes in which the DNA segments encoding mouse variable regions specific for the hapten trinitrophenyl (TNP) are joined to segments encoding human μ and κ constant regions.
Related Papers (5)
Continuous cultures of fused cells secreting antibody of predefined specificity
G Köhler,C. Milstein +1 more